Serum Antibodies Against the E5 Oncoprotein from Human Papillomavirus Type 16 Are Inversely Associated with the Infection and the Degree of Cervical Lesions
2024

Anti-E5 Antibodies and Cervical Cancer

Sample size: 485 publication 10 minutes Evidence: moderate

Author Information

Author(s): Salazar-Piña Azucena, Maldonado-Gama Minerva, Gonzalez-Jaimes Ana M., Cruz-Valdez Aurelio, Ortiz-Panozo Eduardo, Esquivel-Guadarrama Fernando, Gutierrez-Xicotencatl Lourdes

Primary Institution: Facultad de Nutrición, Universidad Autónoma del Estado de Morelos, Cuernavaca, Mexico

Hypothesis

The study aimed to characterize the antibody response against HPV16 E5 in the natural history of cervical cancer and to determine its usefulness as a biomarker of HPV-associated cervical lesions.

Conclusion

The presence of anti-E5 antibodies is associated with the clearance of HPV infection in women without lesions and with CIN1 lesions, while their absence correlates with the progression to cervical cancer.

Supporting Evidence

  • Anti-E5 antibodies were found in 49.4% of women without lesions.
  • The prevalence of anti-E5 antibodies decreased with the severity of cervical lesions.
  • Women with CIN1 lesions had a statistically significant drop in anti-E5 antibody levels compared to those without lesions.
  • Logistic regression showed negative associations of anti-E5 antibodies with CIN1, CIN2, and CIN3/CC.

Takeaway

This study found that women without cervical lesions have more anti-E5 antibodies, which might mean their HPV infection is cleared, while those with more severe lesions have fewer antibodies.

Methodology

The study involved 335 women with cervical lesions and 150 women with negative Papanicolaou tests, using PCR for HPV genotyping and slot blot for anti-E5 antibody detection.

Limitations

The study had a low sensitivity in detecting HPV types, which may have affected the results.

Participant Demographics

Women aged 18 to 64 years from Cuautla General Hospital, Morelos, Mexico.

Statistical Information

P-Value

p<0.001 for CIN1, p<0.01 for CIN2

Confidence Interval

95% CI 0.22–0.67 for CIN1, 95% CI 0.19–0.91 for CIN2, 95% CI 0.12–0.82 for CIN3/CC

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/biomedicines12122699

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication